Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 3/2014

01-09-2014 | Original Article

BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan

Authors: Ida Biunno, Gitana Aceto, Khalid Dafaallah Awadelkarim, Annalisa Morgano, Ahmed Elhaj, Elgaylani Abdalla Eltayeb, Dafalla Omer Abuidris, Nasr Eldin Elwali, Chiara Spinelli, Pasquale De Blasio, Ermanna Rovida, Renato Mariani-Costantini

Published in: Familial Cancer | Issue 3/2014

Login to get access

Abstract

Premenopausal breast cancer (BC) is one of the most common cancers of women in rural Africa and part of the disease load may be related to hereditary predisposition, including mutations in the BRCA1 gene. However, the BRCA1 mutations associated with BC in Africa are scarcely characterized. We report here 33 BRCA1 point mutations, among which 2 novel missense variants, found in 59 Central Sudanese premenopausal BC patients. The high fractions of mutations with intercontinental and uniquely African distribution (17/33, 51.5 % and 14/33, 42.4 %, respectively) are in agreement with the high genetic diversity expected in an African population. Overall 24/33 variants (72.7 %) resulted neutral; 8/33 of unknown significance (24.3 %, including the 2 novel missense mutations); 1 (3.0 %) overtly deleterious. Notably, in silico studies predict that the novel C-terminal missense variant c.5090G>A (p.Cys1697Tyr) affects phosphopeptide recognition by the BRCA1 BRCT1 domain and may have a pathogenic impact. Genetic variation and frequency of unique or rare mutations of uncertain clinical relevance pose significant challenges to BRCA1 testing in Sudan, as it might happen in other low-resource rural African contexts.
Literature
1.
Pagani F, Baralle FE (2004) Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5(5):389–396PubMedCrossRef
2.
Plon SE, Eccles DM, Easton D et al (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29(11):1282–1291PubMedPubMedCentralCrossRef
3.
Lee MS, Green R, Marsillac SM et al (2010) Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 70(12):4880–4890PubMedPubMedCentralCrossRef
4.
Walker LC, Whiley PJ, Couch FJ et al (2010) Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 31(6):E1484–E1505PubMedPubMedCentralCrossRef
5.
Williams RS, Glover JN (2003) Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem 278(4):2630–2635PubMedCrossRef
6.
Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV (2006) Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34(5):1317–1325PubMedPubMedCentralCrossRef
7.
Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A (2007) Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3(2):e26PubMedPubMedCentralCrossRef
8.
9.
Thery JC, Krieger S, Gaildrat P et al (2011) Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet 19(10):1052–1058PubMedPubMedCentralCrossRef
10.
Coquelle N, Green R, Glover JN (2011) Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Biochemistry 50(21):4579–4589PubMedPubMedCentralCrossRef
11.
12.
Campbell MC, Tishkoff SA (2008) African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomic Hum Genet 9:403–433CrossRef
13.
Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C (2003) Breast cancer genetics in African Americans. Cancer 97(1 Suppl):236–245PubMedCrossRef
14.
Oluwagbemiga LA, Oluwole A, Kayode AA (2012) Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa?—a systematic review. Springerplus 1(1):83PubMedPubMedCentralCrossRef
15.
Fackenthal JD, Zhang J, Zhang B et al (2012) High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer 131(5):1114–1123PubMedCrossRef
16.
Mariani-Costantini R (2013) Diagnosis: breast cancer screening in rural African communities. Nat Rev Clin Oncol 10(4):185–186PubMedCrossRef
17.
Awadelkarim KD, Elhaj A, Aceto G, Mariani-Costantini R, Eltayeb EA (2012) Hereditary breast cancer in Sub-Saharan Africa. Curr Women’s Health Rev 8(1):44–54CrossRef
18.
Awadelkarim KD, Arizzi C, Elamin EO et al (2008) Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology 52(4):445–456PubMedCrossRef
19.
Awadelkarim KD, Mariani-Costantini R, Elwali NE (2012) Cancer in the Sudan: an overview of the current status of knowledge on tumor patterns and risk factors. Sci Total Environ 9(423):214–228CrossRef
20.
Awadelkarim KD, Aceto G, Veschi S et al (2007) BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat 102(2):189–199PubMedCrossRef
21.
Malferrari G, Monferini E, DeBlasio P et al (2002) High-quality genomic DNA from human whole blood and mononuclear cells. Biotechniques 33(6):1228–1230PubMed
22.
Gross E, Arnold N, Pfeifer K, Bandick K, Kiechle M (2000) Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum Mutat 16(4):345–353PubMedCrossRef
23.
24.
Zhang J, Fackenthal JD, Huo D, Zheng Y, Olopade OI (2010) Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat 124(2):573–577PubMedCrossRef
25.
Lindor NM, Guidugli L, Wang X et al (2011) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33(1):8–21PubMedPubMedCentralCrossRef
26.
Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A (2008) Classification of rare missense substitutions, using risk surfaces, with genetic-and molecular-epidemiology applications. Hum Mutat 29(11):1342–1354PubMedPubMedCentralCrossRef
27.
Altshuler DM, Gibbs RA, Peltonen L et al (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52–58PubMedCrossRef
28.
Tavtigian SV, Deffenbaugh AM, Yin L et al (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43(4):295–305PubMedPubMedCentralCrossRef
29.
30.
31.
32.
Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C (2009) Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37(9):e67PubMedPubMedCentralCrossRef
33.
Williams RS, Green R, Glover JN (2001) Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8(10):838–842PubMedCrossRef
34.
Berman H, Henrick K, Nakamura H (2003) Announcing the worldwide protein data bank. Nat Struct Biol 10(12):980PubMedCrossRef
35.
Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779–815PubMedCrossRef
36.
37.
Guerois R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 320(2):369–387PubMedCrossRef
38.
el El-Harith HA, Abdel-Hadi MS, Steinmann D, Dork T (2002) BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi Med J 23(6):700–704
39.
Chen X, Truong TT, Weaver J et al (2006) Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 27(5):427–435PubMedCrossRef
40.
Scholl T, Pyne MT, Russo D, Ward BE (1999) BRCA1 IVS16+6T–>C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site. Am J Med Genet 85(2):113–116PubMedCrossRef
41.
Judkins T, Hendrickson BC, Deffenbaugh AM, Scholl T (2005) Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat Res 573(1–2):168–179PubMedCrossRef
42.
Spurdle AB, Lakhani SR, Healey S et al (2008) Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis–a report from the kConFab Investigators. J Clin Oncol 26(10):1657–1663PubMedCrossRef
43.
Needham CJ, Bradford JR, Bulpitt AJ, Care MA, Westhead DR (2006) Predicting the effect of missense mutations on protein function: analysis with Bayesian networks. BMC Bioinform 7:405CrossRef
44.
Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105(1):149–160PubMedCrossRef
45.
Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R (1998) The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 273(39):25388–25392PubMedCrossRef
46.
47.
Monteiro AN, August A, Hanafusa H (1996) Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93(24):13595–13599PubMedPubMedCentralCrossRef
48.
Clapperton JA, Manke IA, Lowery DM et al (2004) Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11(6):512–518PubMedCrossRef
49.
Masso M, Vaisman II (2010) AUTO-MUTE: web-based tools for predicting stability changes in proteins due to single amino acid replacements. Protein Eng Des Sel 23(8):683–687PubMedCrossRef
50.
Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34(Web Server issue):W239–W242PubMedPubMedCentralCrossRef
51.
Vallon-Christersson J, Cayanan C, Haraldsson K et al (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10(4):353–360PubMedCrossRef
52.
Nomine Y, Botuyan MV, Bajzer Z et al (2008) Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations. Biochemistry 47(37):9866–9879PubMedPubMedCentralCrossRef
Metadata
Title
BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan
Authors
Ida Biunno
Gitana Aceto
Khalid Dafaallah Awadelkarim
Annalisa Morgano
Ahmed Elhaj
Elgaylani Abdalla Eltayeb
Dafalla Omer Abuidris
Nasr Eldin Elwali
Chiara Spinelli
Pasquale De Blasio
Ermanna Rovida
Renato Mariani-Costantini
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9717-4

Other articles of this Issue 3/2014

Familial Cancer 3/2014 Go to the issue

Review

Duplex value of caveolin-1 in non-small cell lung cancer: a meta analysis

Original Article

How harmful is genetic testing for familial adenomatous polyposis (FAP) in young children; the parents’ experience

Original Article

A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns

Original Article

Nucleotide variants of the cancer predisposing gene CDH1 and the risk of non-syndromic cleft lip with or without cleft palate

Original Article

Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome

Short Communication

Intronic splicing mutations in PTCH1 cause Gorlin syndrome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits